1 / 17

Acrylamide Toxicity: Research to Address Key Data Gaps

Acrylamide Toxicity: Research to Address Key Data Gaps. Presented by Dr. Stephen S. Olin ILSI Risk Science Institute. JIFSAN/NCFST Workshop on Acrylamide in Food. October 28-30, 2002 – Chicago Mechanisms of Formation of Acrylamide in Food Analytical Methods Exposure and Biomarkers

lecea
Télécharger la présentation

Acrylamide Toxicity: Research to Address Key Data Gaps

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Acrylamide Toxicity:Research to Address Key Data Gaps Presented by Dr. Stephen S. Olin ILSI Risk Science Institute

  2. JIFSAN/NCFST Workshop on Acrylamide in Food • October 28-30, 2002 – Chicago • Mechanisms of Formation of Acrylamide in Food • Analytical Methods • Exposure and Biomarkers • Toxicology and Metabolic Consequences • Risk Communication

  3. Toxicity Focus Areas • Kinetics and Metabolism • Genetic Toxicity • Reproductive and Developmental Toxicity • Carcinogenicity • Neurotoxicity • Epidemiology

  4. Acrylamide Toxicology Research Themes • Assess the significance of adverse effects observed at high doses for low-level human exposures in foods • Assess the significance for humans of effects observed in vitro or in vivo in rodents

  5. Kinetics, Metabolism & Modes of Action:Research Needs • Critical events and dose metrics related to modes of action (MoA) for key acrylamide toxicities • Metabolic fate and kinetics in humans • Physiologically-based pharmacokinetic models

  6. Kinetics, Metabolism & Modes of Action:Ongoing/Planned Research • Critical events/dose metrics/MoA – • FDA/NCTR – Linked to NTP bioassay • NIEHS – CYP 2E1 null mouse studies • Metabolism/kinetics in humans – • Several groups – RTI, CDC/NHANES, Stockholm U., Kaiserslautern U., others • PBPK models – • Kirman et al. (2003) – Rat model; others?

  7. Genetic Toxicity:Research Needs • Identification and characterization of adducts of acrylamide and/or glycidamide with DNA and significant nuclear proteins • Biological relevance • Species and dose dependence, in vitro and in vivo • Investigation of mechanisms of specific effects (e.g., chromosomal effects, cell transformation)

  8. Genetic Toxicity:Ongoing/Planned Research • DNA and protein adducts – • FDA/NCTR – DNA and protein adducts (including dose response) • Industry – DNA adducts in vitro and in vivo • Genetic toxicity mechanisms – • FDA/NCTR - In vivo mutagenicity in Big Blue and tk+/- mice • Industry - Interaction with kinesin-related proteins

  9. Reproductive and Developmental Toxicity: Research Needs • Dose-response data for germ cell toxicity in rodents • Role of acrylamide vs. glycidamide • Further examination of potential for developmental neurotoxicity

  10. Reproductive and Developmental Toxicity: Ongoing/Planned Research • Germ cell toxicity – • NIEHS – CYP 2E1 null mouse dominant lethal study • Developmental neurotoxicity – • FDA/NCTR – TBD • Academic – Mechanistic studies

  11. Carcinogenicity:Research Needs • Confirm and clarify carcinogenicity in standard rodent models • Pathology working group review • Assess effects of perinatal exposure • Develop enhanced data for dose-response assessment • Determine mechanisms of induction of key tumors

  12. Carcinogenicity:Ongoing/Planned Research • Clarify carcinogenicity – • NTP/NCTR – Well-designed 2-year studies of acrylamide in rats and mice • NTP/NCTR – Neonatal mouse studies (acrylamide and glycidamide) • NIEHS – PWG review of previous studies? • Mechanisms – • NTP/NCTR – In conjunction w/2-year studies? • Industry – Thyroid, brain, cell proliferation

  13. Neurotoxicity:Research Needs • Relationships between dose, duration, and effect-levels and onset of neurotoxicity • Determine effects of low-level, long-term dietary exposures • Link damage at cellular/tissue level with functional changes • Mechanisms of neurotoxicity • Role of acrylamide vs. glycidamide vs. ? • Bridge effects in animals and humans

  14. Neurotoxicity:Ongoing/Planned Research • Dose/duration/effect/onset – • FDA/NCTR – Ancillary studies with 2-year rodent bioassays to assess cumulative damage from low-level dietary exposures? • Mechanisms - • Academic – Nerve terminal damage, axonal transport, key proteins, etc. • NIEHS – CYP 2E1 null mouse, antioxidant, Phase II enzyme inhibitor • NIOSH – Markers in exposed workers

  15. Epidemiology:Research Needs • Study new or previously evaluated exposed worker cohorts for specific effects • Link biomarkers of exposure with effects in workers • Assess feasibility and design criteria for study of acrylamide exposure/effects in non-occupationally exposed populations

  16. Epidemiology:Ongoing/Planned Research • Specific effects in workers – • NIOSH – Reproductive and neurobehavioral • Industry – Reassessment of published studies • Biomarkers – • NIOSH – Biomarkers included • Feasibility/design of study of non-occupationally exposed population – • CDC/NHANES, EPIC • See, e.g., Mucci et al., 2003

  17. Conclusions • Ongoing/planned research (including FDA/NCTR work) will address many of the important toxicology research needs. • Key objectives include developing PBPK model for humans and understanding the significance of high-dose carcinogenic and neurotoxic effects for low-level exposures to acrylamide in foods.

More Related